Sell to close the April 21, 2017 call on The Chemours Company (CC) with a strike price of $29.00 at $4.49 or higher (Symbol (CC170421C29)) for a 140% gain in three short trading days. Chemours bulls got a nice boost today due to a litigation settlement announced this morning. I still… Read More
Analyst Articles
I recommended The Chemours Company stock (NYSE: CC) earlier today. For those subscribers who prefer option trades, I recommend the following: Buy to open the April 21, 2017 call on The Chemours Company (CC) with a strike price of $29.00 at $1.85 or lower. Symbol (CC170421C29)… Read More
The Chemours Company (NYSE: CC) is one of two publicly traded companies able to cash in on on a major worldwide regulatory change regarding chemicals used as refrigerants. Chemours’ Opteon is one of two acceptable substitutes for current refrigerants. Target: $48 Buy Up To: $30 The Kigali agreement, signed in November… Read More
Buy Jazz Pharmaceuticals (NSDQ: JAZZ) up to $130 per share. Jazz Pharma is both profitable and fast growing – an unusual combination in its industry. Its recent acquisition of Celator Pharmaceuticals last fall gives it a new drug candidate for Acute Myeloid Leukemia (AML). In the meantime, the company… Read More
Air Transport Services Group gave preliminary results for its fourth quarter, lowering adjusted earnings guidance by $7 million due to the work stoppage of union pilots. Despite the bad news, the stock rallied slightly, as investors had feared the hit to earnings would be higher. Air Transport will give guidance on… Read More
Sell to close the February 17, 2017 put on Post Holdings (POST) with a strike price of $85.00 at $3.00 or higher. Read More
Many of the positions I take for Profit Catalyst Alert are informed by company conference calls, and one is taking place Friday I think you’ll be interested in–and which will show some of the triggers I look for so you can get a front seat into how I do what… Read More
It’s been a might fine cruise with boat maker Brunswick (NYSE: BC); its stock is up 45% since my recommendation one year ago. The boating market has remained firm allowing the company to grow earnings at a stable mid-teens rate. Its diversification into the fitness sector should help it weather… Read More
ANI Pharma (NSDQ: ANIP) is one of the few drug makers that has escaped market fears of price controls. Although its stock has almost doubled in the past year, I expect it could rise another 65%. Target $100 Buy Up To: $68 With three quarters of its revenue derived… Read More
Acuity (NYSE: AYI) got hit hard last week due to an analyst downgrade. Roth Capital downgraded the stock to a sell based on President Trump’s threat of a 20% tariff on imports from Mexico. The analyst noted that a large portion of Acuity’s parts would be affected. It is impossible… Read More